Antibody

69개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved69 programs
AntibodyLimited DatastaleEli Lilly and CompanyPhase 2

cixutumumab (IMC-A12, IMC-A12 (cixutumumab))

Non-Small Cell Lung Cancer · Colon Cancer

#ColonCancer#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+1
Trials 2Status Active
AntibodyLimited DatastaleRoswell Park Cancer InstitutePhase 1

Nimotuzumab (Nimotuzumab)

EGFR Gene Mutation; Recurrent Non-Small Cell Lung Carcinoma · Advanced Cancer

#AdvancedCancer#Antibody#Phase1#monoclonal-antibody#EGFRGeneMutation+2
Trials 2Status Active
AntibodyLimited DatastaleThe First Affiliated Hospital o…Phase 2

Adebrelimab Combined with Bevacizumab and Docetaxel (Adebrelimab Combined with Bevacizumab and Docetaxel)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#The
Trials 1Status Active
AntibodyLimited DatastaleKymab LimitedPhase 2

Alomfilimab (Alomfilimab)

Squamous Cell Carcinoma of Head and Neck; Non-small Cell Lung Cancer · Squamous Cell Carcinoma of Head and Neck

#SquamousCellCarcinomaofHeadandNe#Antibody#Phase2#monoclonal-antibody#Non-smallCellLungCancer+1
Trials 1Status Discontinued
AntibodyLimited DatastaleGustave Roussy, Cancer Campus, …Phase 2

atezolizumab (Tecentriq, Anti-PD-L1 antibody atezolizumab)

Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma ) · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#PatientsWithMetastaticTumoursCol+3
Trials 1Status Active
AntibodyLimited DatastaleNational Cancer Center, KoreaPhase 2

nivolumab (Opdivo, CA and Nivolumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#National
Trials 1Status Active
AntibodyLimited DatastaleCorvus Pharmaceuticals, Inc.Phase 1

pembrolizumab (Keytruda, CPI-006 + pembrolizumab)

Non-Small Cell Lung Cancer; Renal Cell Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase1#monoclonal-antibody#RenalCellCancer+1
Trials 1Status Active
AntibodyLimited DatastaleIdris BahceApproved

durvalumab (Imfinzi, Consolidation durvalumab)

Non-small Cell Lung Cancer Stage III · Non-small Cell Lung Cancer Stage III

#Non-smallCellLungCancerStageIII#Antibody#Approved#monoclonal-antibody#Idris
Trials 1Status Recruiting
AntibodyLimited DatastaleDizal PharmaceuticalsPhase 2

DZD9008 plus Bevacizumab (DZD9008 plus Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Dizal
Trials 1Status Recruiting
AntibodyLimited DatastaleGilead SciencesPhase 2

DOM (Domvanalimab, Domvanalimab (DOM))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#monoclonal-antibody#AdvancedorMetastaticNon-Small-Ce+1
Trials 1Status Recruiting
AntibodyLimited DatastaleCelgenePhase 2

Duravalumab (Duravalumab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#monoclonal-antibody#Carcinoma+2
Trials 1Status Active
AntibodyLimited DatastaleBristol-Myers SquibbPreclinical

nivolumab (Opdivo, Immuno-oncology-based therapy, excluding nivolumab-based regimens, Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy)

Non-small Cell Lung Cancer (NSCLC) · Non-small Cell Lung Cancer (NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Preclinical#monoclonal-antibody#Bristol-Myers
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 3

Bevacizumab Biosimilar Drug (MB02, MB02 (Bevacizumab Biosimilar Drug))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleAssistance Publique Hopitaux De…Phase 2

IPH2201 (Monalizumab, Monalizumab (IPH2201))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Assistance
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

atezolizumab (Tecentriq, N-803 + Atezolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

atezolizumab (Tecentriq, N-803 + Atezolizumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

N-803 + Avelumab (N-803 + Avelumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

N-803 + Avelumab + PD-L1 t-haNK (N-803 + Avelumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

nivolumab (Opdivo, N-803 + Docetaxel + Nivolumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab (Keytruda, N-803 + Docetaxel + Pembrolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting

2 / 4 pages

← PreviousNext →